ArticleFrontiers in pediatrics2026
Pediatric oral antihypertensive agents: analysis of prescription patterns and patient characteristics in a real-world study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to assess prescribing intensity and rational dosing of antihypertensives in children using Defined Daily Dose (DDD) and Drug Utilization Index (DUI). Methods: A retrospective cross-sectional analysis was conducted on all antihypertensive prescriptions dispensed at a tertiary children's hospital from May 2023 to April 2024, excluding those with incomplete data or on fixed-dose combinations. Prescription medicine use is basically reasonable when DUI is close to 1 (0.9-1.1), a DUI >1.1 suggests that the actual daily dose exceeds DDD, while a DUI <0.9 indicates underdosing. Statistical analysis was performed using SPSS 23.0 with significance at Results: A total of 1,562 prescriptions for 422 children (12-18 years; 76.30% male) were analysed; prevalence peaked at 13 years. Among over-12-year-olds, DUI <0.9 for β-blockers, spironolactone and nifedipine; DUI ≈ 1 for furosemide, captopril and losartan; DUI >1.1 for hydrochlorothiazide, amlodipine, ramipril and fosinopril. Amlodipine comprised 42.8% of total DDDs, followed by fosinopril (25.6%) and ramipril (20.0%). Males showed borderline higher DUI values. Conclusions: Hypertension was most prevalent among 13- to 14-year-old, who also exhibited the highest antihypertensive exposure and drug-use intensity relative to girls. Once-daily formulations accounted for the majority of prescriptions. Pediatric oral hypertension dosing remains inconsistent in clinical practice. These findings support sex-specific management and guideline updates to improve blood pressure control in high-risk adolescents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.